Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Rhea-AI Summary

NeOnc Technologies (NASDAQ:NTHI) focuses on CNS oncology drug delivery. Its lead oral program NEO212 is a next-generation temozolomide designed to improve blood-brain barrier penetration and address MGMT-driven resistance in glioblastoma. Phase 1 dose escalation completed with a Recommended Phase 2 Dose of 610 mg and early signs of disease control observed. Intranasal NEO100 showed Phase 2 radiographic responses and improved progression-free survival versus historical salvage benchmarks. The company also completed a PIPE adding a gross $16.0M to its balance sheet.

Positive

• Phase 1 complete with a 610 mg recommended Phase 2 dose
• Early signs of disease control observed in recurrent GBM
• NEO100 Phase 2 showed radiographic responses and improved PFS
• $16.0M PIPE added gross proceeds to the balance sheet

Negative

• No completed Phase 2 efficacy data yet for NEO212
• Clinical benefits described as early signs, not definitive outcomes
• $16.0M PIPE may dilute shareholders or provide limited runway

News Market Reaction – NTHI

-4.36%

2 alerts

-4.36% News Effect

+9.6% Peak Tracked

-$10M Valuation Impact

$215M Market Cap

1.0x Rel. Volume

On the day this news was published, NTHI declined 4.36%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $215M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PIPE gross proceeds: $16.0M NEO212 RP2D: 610 mg

2 metrics

PIPE gross proceeds $16.0M Recent PIPE offering mentioned as added to balance sheet

NEO212 RP2D 610 mg Recommended Phase 2 Dose from completed Phase 1 in recurrent GBM

Market Reality Check

Price: $8.65 Vol: Volume 13,768 is at 0.36x...

low vol

$8.65 Last Close

Volume Volume 13,768 is at 0.36x the 20-day average of 38,761, indicating subdued trading ahead of this update. low

Technical Shares at 9.41 were trading above the 200-day MA of 8.11 before the announcement, reflecting an established uptrend despite recent weakness.

Peers on Argus

Momentum data show no peers in the scanner, while broader biotech peers had mixe...

Momentum data show no peers in the scanner, while broader biotech peers had mixed moves (e.g., TRDA up 3.77%, several others down), suggesting this coverage update and clinical/PIPE context are company‑specific rather than sector‑driven.

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Phase 1 results	Positive	+4.9%	Full Phase 1 NEO212 dose-escalation results and RP2D set at 610 mg.
Feb 27	Conference call	Positive	+1.3%	Announcement of investor call to present initial NEO212 Phase 1 data.
Jan 30	PIPE financing	Positive	+5.9%	Strategic PIPE with up to 2,222,222 shares and warrants targeting $16M gross.
Jan 09	Coverage initiation	Positive	-3.5%	Stonegate initiation highlighting NEO100 intranasal strategy and upcoming catalysts.
Dec 15	Clinical update	Positive	-3.2%	Updated intranasal NEO100 data showing remission and survival benefits in astrocytoma.

Pattern Detected

Recent clinically focused and financing news usually led to positive price reactions, but some strong NEO100 data saw negative moves, indicating occasional divergences.

Recent Company History

Over the last few months, NeOnc has combined clinical progress with active capital markets activity. On Dec 15, 2025, updated intranasal NEO100 data in recurrent astrocytoma showed meaningful remission and survival metrics but the stock fell. Subsequent coverage initiation on Jan 9, 2026 also coincided with a decline. By contrast, the Jan 30, 2026 PIPE financing targeting up to $16 million and the late‑February/early‑March NEO212 Phase 1 readout and call produced price gains. Today’s coverage update and reiteration of NEO212/NEO100 momentum aligns more closely with those positive clinical and financing milestones.

Market Pulse Summary

This announcement reinforces NeOnc’s positioning as a CNS oncology platform company, highlighting NE...

Analysis

This announcement reinforces NeOnc’s positioning as a CNS oncology platform company, highlighting NEO212’s completed Phase 1 work with a 610 mg RP2D and NEO100’s Phase 2 signals in recurrent GBM. It also references a recent PIPE that added $16.0M to the balance sheet. In context of earlier NEO212 updates and recent financings, investors may watch for Phase 2 trial initiations, regulatory interactions, and further capital-raising steps as key future catalysts.

Key Terms

blood-brain barrier, bbb, mgmt, glioblastoma, +3 more

7 terms

blood-brain barrier medical

"developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

bbb medical

"developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug"

bbb is a mid-level credit rating that signals an issuer or bond is financially stable but more vulnerable to adverse conditions than higher-rated peers. Think of it like a middle-of-the-road safety score for a car: it’s acceptable for everyday use but not the safest option in extreme conditions. For investors, a bbb rating matters because it influences borrowing costs, expected returns and portfolio rules about how much risk is acceptable, with lower ratings typically offering higher yields to compensate for greater risk.

mgmt medical

"address key limitations of current treatment including BBB penetration and MGMT-driven resistance"

Mgmt is short for management, meaning the group of executives and senior staff who run a company and make strategic, financial, and operational decisions. Investors care because the quality and choices of this ‘captain and crew’ determine how well a company executes plans, uses money, and responds to problems — directly affecting profits, risk, and the value of shares.

glioblastoma medical

"resistance in glioblastoma (GBM), targeting a large population where standard TMZ therapy"

Glioblastoma is a fast-growing and aggressive type of brain tumor that can affect a person's thinking, movement, or senses. Its seriousness and difficulty to treat can lead to significant health impacts, making it a concern for medical research and drug development. For investors, advances or setbacks in glioblastoma treatments can influence biotech companies and healthcare markets focused on cancer therapies.

progression-free survival medical

"Phase 2 data showing radiographic responses and improved progression-free survival versus"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

phase 1 medical

"Phase 1 dose escalation in recurrent GBM has completed with a Recommended Phase 2 Dose"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"Recommended Phase 2 Dose of 610 mg established and early signs of disease control"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. Not financial advice.

Dallas, Texas--(Newsfile Corp. - March 12, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company's lead program, NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy used in most brain cancer patients. It is designed to address key limitations of current treatment including BBB penetration and MGMT-driven resistance. Its platform includes NEO100 and NEO212, discussed in further detail below. Beyond its lead programs, NeOnc's platform approach combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. Lastly, NTHI recently led a successful PIPE offering, adding a gross $16.0M to the Company's balance sheet.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• NEO212 (oral chemotherapy): A next-generation version of temozolomide designed to improve blood-brain barrier penetration and overcome MGMT-driven resistance in glioblastoma (GBM), targeting a large population where standard TMZ therapy frequently fails.
• NEO212 clinical momentum: Phase 1 dose escalation in recurrent GBM has completed with a Recommended Phase 2 Dose of 610 mg established and early signs of disease control observed, positioning the program to advance into Phase 2 efficacy evaluation.
• NEO100 (intranasal therapy): A non-invasive drug delivery approach targeting recurrent GBM, with Phase 2 data showing radiographic responses and improved progression-free survival versus historical salvage benchmarks.

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288256

FAQ

What milestone did NeOnc Technologies (NTHI) announce on March 12, 2026 regarding NEO212?

NeOnc established a Recommended Phase 2 Dose of 610 mg after Phase 1 dose escalation. According to the company, Phase 1 completed and early signs of disease control were observed, positioning NEO212 to enter Phase 2 efficacy evaluation.

How did NeOnc describe clinical results for intranasal NEO100 in recurrent GBM?

NEO100 showed radiographic responses and improved progression-free survival versus historical salvage benchmarks. According to the company, these Phase 2 data support intranasal delivery as a non-invasive CNS drug-penetration approach.

What was the financial update for NeOnc Technologies (NTHI) on March 12, 2026?

NeOnc completed a PIPE that added a gross $16.0M to the company's balance sheet. According to the company, proceeds are intended to support ongoing clinical programs and corporate operations.

Does NEO212 address temozolomide limitations for glioblastoma patients?

NEO212 is described as a next-generation temozolomide designed to improve BBB penetration and overcome MGMT-driven resistance. According to the company, the program targets patients where standard TMZ frequently fails.

What are the near-term development steps for NeOnc's lead programs (NTHI)?

The near-term step is advancing NEO212 into Phase 2 efficacy evaluation after dose escalation. According to the company, Phase 1 completed with a recommended 610 mg dose and early disease-control signals were reported.